Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Busse has provided advisory board services to Merck & Co, Inc and consulting services to Amgen Inc; Novartis AG; GlaxoSmithKline plc; MedImmune, LLC; and Genentech, Inc. He also has received royalties from Elsevier BV and National Institutes of health (NIH) university grant monies from the National Institute of Allergy and Infectious Diseases and National Heart, Lung, and Blood Institute. Dr Calhoun reports grant funding from the NIH and Alcon Laboratories, Inc and consultant income from Genentech, Inc and Merck & Co, Inc. Dr Castro served as consultant or on the advisory board for Genentech, Inc; Innovative Pulmonary Solutions, Inc; MedImmune, LLC; NKT Therapeutics, Inc; and Schering-Plough. He lectured for Asthmatx/Boston Scientific Corporation, AstraZeneca; Boehringer Ingelheim GmbH; Genentech, Inc; GlaxoSmithKline plc; Merck & Co, Inc; and Pfizer, Inc. His university received industry-sponsored grants from Amgen Inc; Asthmatx/Boston Scientific Corporation; Ception Therapeutics, Inc/Cephalon, Inc; Genentech, Inc; GlaxoSmithKline plc; MedImmune, LLC; Merck & Co, Inc; Novartis AG, and sanofi-aventis US LLC. Dr Castro’s university received grant monies from the NIH and the American Lung Association, and he has received royalties from Elsevier BV. Dr Chung has received university grant monies from the Wellcome Trust, Medical Research Council, Asthma UK, NIH, and National Environmental Research Council (UK). He has also been remunerated for participating at advisory board meetings with GlaxoSmithKline plc and Gilead and for participating in speaking activities at the invitation of Novartis AG and GlaxoSmithKline plc. Drs Rao, Moore, Bleecker, Erzurum, Israel, Curran-Everett, and Wenzel have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.